Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Long-term Extension Study of Ligelizumab in Food Allergy
NCT05678959 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2026-01-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-11Phase 3 first posted: Novartis Pharmaceuticals, Remibrutinib + Omalizumab (NCT07816328)
- 2026-05-29Results posted on the registry: Stanford University, Omalizumab + Dupilumab (NCT03679676)
- 2025-11-21Also stopped (terminated): BioRay Pharmaceutical Co., Ltd., HS632 + Omalizumab (Xolair®) (NCT04361812)
- 2025-10-23Results posted on the registry: Sanofi, Dupilumab + Omalizumab (NCT04998604)
- 2025-10-07Results posted on the registry: Teva Pharmaceuticals USA, TEV-45779 + XOLAIR® Injection (NCT04976192)
- 2025-08-20Results posted on the registry: Sanofi, Dupilumab SAR231893 + Placebo (NCT04180488)
- 2025-07-29Results posted on the registry: Celltrion, CT-P39 + EU-approved Xolair (NCT04426890)
- 2025-04-29Also stopped (terminated): Novartis Pharmaceuticals, ligelizumab + Placebo (NCT04984876)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision